SENS 2 Report, John Furber

Another of Frank Rummel's reports from the recent Strategies for Engineered Negligible Senescence conference (SENS 2) is up, with a focus on John Furber of Legendary Pharmaceuticals. As his SENS 2 presentation makes clear, Furber is involved in the search for AGE-breakers - drugs or therapies capable of breaking down the detrimental accumulation of advanced glycation end products (AGEs) and crosslinked proteins with age. "Extracellular aging - accumulating molecular damage by glycation, oxidation, and crosslinking of long-lived extracellular proteins, mainly collagen and elastin - is a major cause of several important human aging pathologies." This is an interesting area of study, and perhaps the field of SENS most likely to benefit from traditional approaches to drug discovery and medical research.



Post a comment; thoughtful, considered opinions are valued. New comments can be edited for a few minutes following submission. Comments incorporating ad hominem attacks, advertising, and other forms of inappropriate behavior are likely to be deleted.

Note that there is a comment feed for those who like to keep up with conversations.